Last reviewed · How we verify
MCLA-129
At a glance
| Generic name | MCLA-129 |
|---|---|
| Also known as | bispecific |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. (PHASE1, PHASE2)
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (PHASE1, PHASE2)
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (PHASE1, PHASE2)
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. (PHASE2)
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCLA-129 CI brief — competitive landscape report
- MCLA-129 updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI